
Advent France Biotechnology and Invivo back Arthex Biotech
Advent France Biotechnology and Invivo Ventures have invested EUR4.25 million into Valencia-based Arthex Biotech, a pre-clinical stage life sciences company focused on the development of next generation antisense RNA therapies. The latest round follows on from an initial seed round of EUR2.7 million by Invivo and CDTI-Innvierte in December 2019,
